Dylan Malayter serves as the Senior Vice President and General Manager of the Reagent Solutions Division at Bio-Techne, where he plays a pivotal role in steering the strategic direction of the Recombinant Protein, Antibody, and Small Molecule business units. With a robust background in lifesciences...
Dylan Malayter serves as the Senior Vice President and General Manager of the Reagent Solutions Division at Bio-Techne, where he plays a pivotal role in steering the strategic direction of the Recombinant Protein, Antibody, and Small Molecule business units. With a robust background in lifesciences and a strong technical acumen, Dylan is adept at translating complex scientific concepts into actionable strategies that drive product innovation and enhance customer engagement. His leadership style emphasizes collaboration, ownership, and clear communication, fostering a high-performing team environment that thrives on shared goals.
Under Dylan's guidance, the Reagent Solutions Division is committed to developing high-quality, cutting-edge products that meet the evolving needs of the biopharmaceutical industry. He is particularly focused on integrating advanced technologies into assay development and drug discovery processes, ensuring that Bio-Techne remains at the forefront of innovation. His expertise in regulatory affairs and technology transfer further strengthens the division's capabilities, allowing for seamless transitions from research to market-ready solutions.
Key projects under Dylan's leadership include the launch of novel recombinant proteins and antibodies that address critical gaps in immunology and biochemistry research. By prioritizing a world-class customer experience, he ensures that clients not only receive exceptional products but also benefit from comprehensive support throughout their research and development journeys. Dylan's strategic vision and commitment to excellence position the Reagent Solutions Division as a leader in the life sciences sector, driving advancements that ultimately contribute to improved healthcare outcomes.
